Clene Inc. CLNN Archives - Page 5 of 10

TuesdayJul 23, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative…

ThursdayJul 18, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a…

WednesdayJul 17, 2024 1:05 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at the 73rd Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). The company is presenting at the 73rd Emerging Growth Conference, scheduled for July 17-18, 2024. Clene’s presentation is slated to begin at 4:45 p.m. EDT on July 18, with Rob Etherington, Clene’s President and CEO, and Morgan Brown, Clene’s CFO, giving the presentation. To view the full press release, visit https://ibn.fm/Ev3fc About Clene Inc. Clene (along with…

TuesdayJul 09, 2024 10:45 am

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Effect 1-for-20 Reverse Stock Split

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, today announced that it will effect a 1-for-20 reverse stock split at 12:01 a.m. ET on July 11, 2024. According to the announcement, Clene’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 185634201 and the company’s existing symbol CLNN at the beginning of trading on July 11. The reverse stock split, for which Equiniti Trust Company LLC…

FridayJul 05, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Clene revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado The only current FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023 CNM-Au8 treatment showed improvements in mitochondrial respiration deficits in Rett patient-derived astrocytes Clene (NASDAQ: CLNN), along with its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company specializing in mitochondrial health to address neurological diseases like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment. The data was presented by Dr. Karen Ho, Clene's Vice President…

TuesdayJun 25, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Reveals Important Findings From HEALEY ALS Platform Trial

Clene presented findings on HEALEY ALS at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden The presentation, titled “Long-Term CNM-Au8(R) Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” showcased survival follow-up data CNM-Au8 was found to be safe and well-tolerated during the OLE Clene (NASDAQ: CLNN), through its wholly owned subsidiary, Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). This week, Clene unveiled new…

TuesdayJun 18, 2024 12:00 pm

Clene Inc. (NASDAQ: CLNN) CEO and CFO Present Corporate Updates and Future Plans at 72nd Emerging Growth Conference

Clene’s CEO Rob Etherington and CFO Morgan Brown presented highlights and updates on the company’s pipeline – as well as answering questions from the audience Clene has conducted several clinical trials to test the efficacy of CNM-Au8(R), focusing on the diseases amyotrophic lateral sclerosis and multiple sclerosis CNM-Au8 has shown a favorable safety profile, with over 650 collective years of subject exposure without any major safety signals attributed to CNM-Au8 Negotiations are underway to extend the cash runway into 2025, including potential licensing deals and the exercise of warrants that could bring in up to $130 million in additional capital…

WednesdayJun 05, 2024 2:33 pm

QualityStocksNewsBreaks – Clene Inc. (NASDAQ: CLNN) to Present at Emerging Growth Conference

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced that management will present at the Emerging Growth Conference. Clene’s presentation is slated to begin at 2:20 p.m. on June 12, 2024, and include a corporate presentation with questions and-answers. Interested parties can visit https://ibn.fm/A217J to register for and view the webcast, which will also be available on the Events section of the Clene website. A replay of the presentation will be available as detailed…

TuesdayJun 04, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Updates on ACT-EAP for CNM-Au8(R) Compassionate Use

Clene announced significant updates to their NIH-funded Accelerating Access to Critical Therapies Expanded Access Program (ACT-EAP) for CNM-Au8(R) compassionate use in amyotrophic lateral sclerosis (“ALS”) Clene has optimized its manufacturing, operational, and personnel processes to expand the program’s capacity to accommodate up to 180 participants The ACT-EAP, a collaboration among Clene, Columbia University, and Synapticure, was funded by the Accelerating Access to Critical Therapies for ALS Act (ACT for ALS), signed into law by Congress and President Biden in December 2021 Clene (NASDAQ: CLNN) and its subsidiary, Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company dedicated to improving mitochondrial health and…

FridayMay 24, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Participates in Three Investor Conferences During May 2024, Promoting CNM-Au8(R) Neuronal Health Therapy

Clene recently participated in the Mizuho Neuroscience Summit 2024, the Benchmark 2024 Healthcare House Call Virtual Conference, and the Virtual A.G.P. Healthcare Conference CNM-Au8(R) is oral suspension developed to restore neuronal health and function by increasing energy production and utilization The therapy has been involved in clinical trials and compassionate use programs, accumulating over 600 years of exposure across various neurodegenerative conditions, with no safety concerns reported Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), multiple sclerosis (“MS”), and Parkinson’s disease, recently…

Site Search

Company Search

Tag: Clene Inc. CLNN